Effects of Melatonin Supplementation On Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Abstract

Melatonin is a physiological indoleamine secreted from the pineal gland into the bloodstream. This hormone has antioxidant effects in cardiovascular disease, but the evidence regarding its effects on blood pressure (BP) has not been conclusive. Therefore, we assessed the impact of melatonin supplementation on systolic BP (SBP) and diastolic BP (DBP) through a systematic review and meta—analysis of available randomized controlled trials (RCTs). Medline, Scopus, Web of Science, Cochrane library, and Google scholar (until May 2018) were searched to identify potential RCTs with information on melatonin supplementation and BP. Mean Differences (MD) were pooled using a random-effects model. Standard methods were used for assessment of heterogeneity, sensitivity analysis, and publication bias. Pooling 5 RCTs (6 treatment arms) together identified significant reduction for SBP (MD: −3.43 mmHg, 95% confidence interval (CI): −5.76 to −1.09, p=0.004) and DBP (MD: −3.33 mmHg, 95% CI: −4.57 to −2.08, p<0.001) after supplementation with melatonin compared with control treatment. The sensitivity analysis indicated that the results were robust. We did not observe any evidence regarding publication bias. The findings of this meta-analysis support the overall favorable effect of melatonin supplementation on BP regulation.

Key words

melatonin - blood pressure - meta-analysis - randomized controlled trials

• References

• 1 Kafeshani M, Entezari MH, Karimian J. et al. A comparative study of the effect of green tea and sour tea on blood pressure and lipid profile in healthy adult men. ARYA Atherosclerosis 2017; 13: 109
• 2 Rothwell PM, Howard SC, Dolan E. et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905
• 3 Kearney PM, Whelton M, Reynolds K. et al. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217-223
• 4 Li J-C, Tian J, Wu S-L. et al. Effect of long-term systolic blood pressure trajectory on kidney damage in the diabetic population: A prospective study in a community-based chinese cohort. Chin Med J 2018; 131: 1199
• 5 Ong KL, Cheung BM, Man YB. et al. Prevalence, awareness, treatment, and control of hypertension among united states adults 1999–2004. Hypertension 2007; 49: 69-75
• 6 Carey RM, Whelton PK. 2017 ACC/AHA Hypertension guideline writing committee. Prevention, detection, evaluation, and management of high blood pressure in adults: Synopsis of the 2017 American college of cardiology/american heart association hypertension guideline. Ann Intern Med 2018 168: 351-358
• 7 Ozemek C, Phillips SA, Popovic D. et al. Nonpharmacologic management of hypertension: A multidisciplinary approach. Curr Opin Cardiol 2017; 32: 381-388
• 8 Lin P-H, Tyson CC, Batch BC. et al. Nutrition, lifestyle, and hypertension. in, nutrition in the prevention and treatment of disease. (Fourth Edition) Amsterdam: Elsevier; 2017: 625-655
• 9 Gandhi AV, Mosser EA, Oikonomou G. et al. Melatonin is required for the circadian regulation of sleep. Neuron 2015; 85: 1193-1199
• 10 Alamdari NM, Mahdavi R, Roshanravan N. et al. A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women. Horm Metab Res 2015; 47: 504-508
• 11 Cipolla-Neto J, Amaral F, Afeche S. et al. Melatonin, energy metabolism, and obesity: A review. J Pineal Res 2014; 56: 371-381
• 12 Hardeland R. Melatonin—more than just a pineal hormone. Biomed J Sci Tech Res 2017; 1 doi: 10.26717/BJSTR.2017.01.000351
• 13 Mohammadi-Sartang M, Ghorbani M, Mazloom Z. Effects of melatonin supplementation on blood lipid concentrations: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr 2018; 37 6 Pt A 1943-1954
• 14 Rezvanfar MR, Heshmati G, Chehrei A. et al. Effect of bedtime melatonin consumption on diabetes control and lipid profile. Int J Diabetes Develop Countries 2017; 37: 74-77
• 15 Mohamed M, Srinivasan V, Maestroni G. et al. Melatonin and immune function: clinical significance. In, Melatonin and Melatonergic Drugs in Clinical Practice. Berlin: Springer; 2014: 143-157
• 16 Szewczyk-Golec K, Rajewski P, Gackowski M. et al. Melatonin supplementation lowers oxidative stress and regulates adipokines in obese patients on a calorie-restricted diet. Oxid Med Cell Longev 2017; 2017: 8494107; doi: 10.1155/2017/8494107
• 17 Prado NJ, Ferder L, Manucha W. et al. Anti-Inflammatory effects of melatonin in obesity and hypertension. Curr Hyperten Rep 2018; 20: 45
• 18 Goyal A, Terry PD, Superak HM. et al. Melatonin supplementation to treat the metabolic syndrome: A randomized controlled trial. Diabetol Metab Syndr 2014; 6: 124
• 19 Pakravan H, Ahmadian M, Fani A. et al. The effects of melatonin in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Adv Biomed Res 2017; 6: 40
• 20 Raygan F, Ostadmohammadi V, Bahmani F. et al. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr 2017; pii: S0261-5614(17)31424-3
• 21 Assareh AR, Mobasher A, Alasti M. Effect of melatonin on blood pressure in normotensive patients undergoing selective coronary angiography: Is It effective for premedication?. Iran Heart J 2015; 16: 6-12
• 22 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097
• 23 Higgins JP, Altman DG, Gøtzsche PC. et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
• 24 Follmann D, Elliott P, Suh I. et al. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769-773
• 25 Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011] The Cochrane Collaboration; www cochrane-handbook.org
• 26 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
• 27 Egger M, Smith GD, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
• 28 Agahi M, Akasheh N, Ahmadvand A. et al. Effect of melatonin in reducing second-generation antipsychotic metabolic effects: A double blind controlled clinical trial. Diabetes Metab Syndr 2018; 12: 9-15
• 29 Romo-Nava F, Alvarez-Icaza González D, Fresán-Orellana A. et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord 2014; 16: 410-421
• 30 Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS. Gender differences in cardiovascular disease: Hormonal and biochemical influences. Reprod Sci 2010; 17: 511-531
• 31 Reckelhoff J. Gender differences in the regulation of blood pressure. Hypertension (Dallas, Texas 1979) 2001; 37: 1199
• 32 Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: Meta-analysis of randomized controlled trials. Vascul Health Risk Manage 2011; 7: 577
• 33 Cook NR, Cohen J, Hebert PR. et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155: 701-709
• 34 Raskind MA, Burke BL, Crites NJ. et al. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 2007; 32: 284
• 35 Mann K, Rossbach W, Müller MJ. et al. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 2006; 31: 256-264
• 36 Buijs RM, Kalsbeek A. Hypothalamic integration of central and peripheral clocks. Nat Rev Neurosci 2001; 2: 521
• 37 Bothorel B, Barassin S, Saboureau M. et al. In the rat, exogenous melatonin increases the amplitude of pineal melatonin secretion by a direct action on the circadian clock. Eur J Neurosci 2002; 16: 1090-1098
• 38 Goncharuk VD, Van Heerikhuize J, Dai JP. et al. Neuropeptide changes in the suprachiasmatic nucleus in primary hypertension indicate functional impairment of the biological clock. J Comparat Neurol 2001; 431: 320-330
• 39 Scheer FA, Van Montfrans GA, van Someren EJ. et al. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004; 43: 192-197
• 40 Nishiyama K, Yasue H, Moriyama Y. et al. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. Am Heart J 2001; 141: 13A-17A
• 41 Fabrizio RL, Gaia F, Eleonora F. et al. Vascular endothelial cells and dysfunctions: Role of melatonin. Front Biosci 2013; 5: 119-129
• 42 Mayo JC, Sainz RM, Tan D-X. et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 2005; 165: 139-149
• 43 Nabavi SM, Nabavi SF, Sureda A et al. Anti-inflammatory effects of Melatonin: A mechanistic review. Crit Rev Food Sci Nutr 2018 http://www.tandfonline.com/loi/bfsn20
• 44 Seabra MdLV, Bignotto M, Pinto Jr. LR. et al. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 2000; 29: 193-200